Clinical trials: Isotretinoin
Neuroblastoma
Oral Liquid 13-cis-retinoic Acid (13-CRA)
An open label, randomised, multiple dose, cross-over relative bioavailability and pharmacokinetics trial of a novel oral liquid and capsule formulations of 13-CRA administered to patients from 0 months - < 21 years.
- Trial name
- My-CRA (NCT03291080)
- Testing
- Liquid 13-Cis Retinoic Acid, Extracted capsules 13-CRA
- Where
- 10 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Nova Laboratories Limited
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
This partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone following stem cell transplant in treating patients with…
- Conditions
- Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma
- Trial name
- NCT00026312
- Testing
- Aldesleukin, Dinutuximab, Isotretinoin
- Where
- 197 sites in United States, Australia and 3 more
- Volunteers
- 1,449 people
- Sponsor
- National Cancer Institute (NCI)
CYP2D6 Polymorphism
Effects of Isotretinoin on CYP2D6 Activity
Specific Aim: To investigate if isotretinoin (13-cis-retinoic acid) administration decreases CYP2D6 activity in adolescent patients.
- Trial name
- NCT03076021
- Testing
- Isotretinoin, dextromethorphan
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Washington
High Risk Neuroblastoma
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma
This phase III trial is studying the side effects of giving monoclonal antibody Ch14.18 together with sargramostim, aldesleukin, and isotretinoin after autologous stem cell transplant in treating patients with neuroblastoma.
- Trial name
- NCT01041638
- Testing
- Aldesleukin, Diagnostic Laboratory Biomarker Analysis, Dinutuximab
- Where
- 32 sites in United States
- Volunteers
- 105 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
The purpose of this study is to test see the combined effects of the study drug called Humanized 3F8 (Hu3F8) when used with granulocyte-macrophage colony stimulating factor (GM-CSF).
- Trial name
- NCT03033303
- Testing
- Hu3F8, GM-CSF, Isotretinoin
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ganglioneuroblastoma, Localized Resectable Neuroblastoma
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
This pilot clinical trial studies induction therapy followed by iobenguane I 131 and chemotherapy in treating patients with newly diagnosed high-risk neuroblastoma undergoing stem cell transplant, radiation therapy, and…
- Conditions
- Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma
- Trial name
- NCT01175356
- Testing
- 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Busulfan
- Where
- 25 sites in United States
- Volunteers
- 99 people
- Sponsor
- Children's Oncology Group
Brain Tumors
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
The purpose of this study is to: Find out how safe and effective (by monitoring the good and/or bad effects) treatment with high dose temozolomide, thiotepa and carboplatin with stem cell rescue followed by 13-cis-retinoic acid…
- Trial name
- NCT00528437
- Testing
- temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid
- Where
- 17 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- NYU Langone Health
Acne
ABSORICA in Patients With Severe Recalcitrant Nodular Acne
This is an uncontrolled, open-label study being conducted in approximately 200 healthy males, non-pregnant, non-nursing females, age 12 to 45 years, with severe recalcitrant nodular acne.
- Trial name
- NCT02457520
- Testing
- Isotretinoin
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Neuroblastoma
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
RATIONALE: Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, etoposide, and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00499616
- Testing
- carboplatin, cyclophosphamide, doxorubicin hydrochloride
- Where
- 189 sites in United States, Australia and 4 more
- Volunteers
- 464 people
- Sponsor
- Children's Oncology Group
Severe Nodular Acne
Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne
The purpose of this study is to compare the efficacy and safety of CIP-Isotretinoin and a marketed (generic) formulation of isotretinoin when both are administered twice daily with meals.
- Trial name
- NCT00975143
- Testing
- CIP-Isotretinoin, Isotretinoin
- Where
- 49 sites in United States, Canada
- Volunteers
- 925 people
- Sponsor
- Cipher Pharmaceuticals Inc.
Acne Vulgaris
Weekly Isotretinoin Therapy Study
In current Dermatology practice, options for moderate acne vulgaris remain limited. The mainstay of treatment for moderate acne remains long courses of oral antibiotics despite emerging antibiotic resistance.
- Trial name
- WIT (NCT04594759)
- Testing
- Isotretinoin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Medical University of South Carolina
Anaplastic Medulloblastoma, Medulloblastoma
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
This phase III trial studies different chemotherapy and radiation therapy regimens to compare how well they work in treating young patients with newly diagnosed, previously untreated, high-risk medulloblastoma.
- Trial name
- NCT00392327
- Testing
- Biospecimen Collection, Carboplatin, Cisplatin
- Where
- 185 sites in United States, Australia and 3 more
- Volunteers
- 379 people
- Sponsor
- Children's Oncology Group
Neuroblastoma
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation
The purpose of this study is to see if high-dose 3F8 combined with GM-CSF is better than standard dose 3F8 in treating neuroblastoma. Another purpose of the study is to find out what effects, good and/or bad, 3F8 has on cancer.
- Trial name
- NCT01183416
- Testing
- 3F8 monoclonal antibody and 13-cis-Retinoic Acid
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ganglioneuroblastoma, Nodular, Neuroblastoma
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
This phase II trial studies if dinutuximab, GM-CSF, isotretinoin in combination with irinotecan, and temozolomide (chemo-immunotherapy) can be given safely to patients with high-risk neuroblastoma after Consolidation therapy…
- Trial name
- NCT04385277
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 77 sites in United States, Australia and 2 more
- Volunteers
- 41 people
- Sponsor
- Children's Oncology Group
Neuroblastoma
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
The purpose of this study is to be able to supply an experimental combination of drugs called 3F8 and GM-CSF (also called sargramostim) to patients with high-risk neuroblastoma who may benefit from treatment.
- Trial name
- NCT02100930
- Testing
- Anti-GD2 3F8 Monoclonal Antibody, GM-CSF (granulocyte-macrophage colony-stimulating factor), oral isotretinoin
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acne
Musculoskeletal Effects of Isotretinoin During Acne Treatment in Pediatric Population
This is a prospective study, that will follow participants over their course of treatment on Isotretinoin. All patients who are prescribed Isotretinoin for their acne treatment are registered in iPLEDGE.
- Trial name
- NCT00964119
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Wisconsin, Madison
Neuroblastoma
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
The purpose of this study is to find out what effects, good and/or bad, the combination of 3F8 and GM-CSF has on the patient and the cancer.
- Trial name
- NCT01183884
- Testing
- 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neuroblastoma
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
The purpose of this study is to compare the pharmacokinetics (blood levels) and safety of chimeric (ch) 14.18 manufactured by two independent drug makers (United Therapeutics [UTC] or the National Cancer Institute [NCI]).
- Trial name
- NCT01592045
- Testing
- ch14.18 -NCI, ch14.18-UTC, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
- Where
- 13 sites in United States
- Volunteers
- 28 people
- Sponsor
- United Therapeutics
Neuroblastoma
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow
The purpose of this study is to see find out what effects, good and/or bad, the combination of 3F8 and GM-CSF has on the patient and the cancer.
- Trial name
- NCT01183897
- Testing
- 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neuroblastoma
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma
The purpose of this study is to find out what effects, good and/or bad, the combination of 3F8 and GM-CSF has on the patient and the cancer. Antibodies are made by the body to attack tumors and to fight infections.
- Trial name
- NCT01183429
- Testing
- 3F8 and 13-cis-retinoic acid
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center